生物学的製剤に効果不十分な乾癬性関節炎患者に おけるウパダシチニブ: フェーズ3 無作為化対照SELECT-PsA 2試験のオープンラベル延長試験の3年結果
Clin Exp Rheumatol. 2023;41(11):2286–2297 doi: 10.55563/clinexprheumatol/8l7bbk.
Data from this open-label extension showed the efficacy of upadacitinib observed at 56 weeks was maintained through to 152 weeks in the treatment of patients with PsA. No cumulative adverse effects were observed, and no new safety signals were identified.